PURE Bioscience Reports Second Quarter and Six-Month Results
SAN DIEGO, CA March 17, 2008 — PURE Bioscience (OTCBB: PURE) today reported revenues for the second fiscal quarter ended January 31, 2008 of approximately $152,400 compared with revenues of $168,800 in the second quarter of the previous year. The Company reported a net loss of approximately $(1,553,700), or $(0.06) per share for the quarter compared with a loss of $(1,008,112), or $(0.04) per share in second fiscal quarter of the previous year.
Revenues for the six month period ended January 31, 2008 were approximately $247,800, as compared with revenues of $196,500 in the same period of the previous year. The Company reported a net loss of approximately $(2,562,400), or $(0.10) per share, compared with a loss of $(1,875,400), or $(0.08) per share, in the previous period.
“For the third consecutive quarter our revenues increased, said Michael L. Krall, President and CEO of PURE Bioscience. “More importantly, discussions and negotiations with key new partners and distributors for our SDC technology have progressed substantially, and we expect to finalize a number of contracts in the near term across multiple industries.
“Additionally, as our current distributors and partners obtain national, state and international approvals and ready their marketing and sales initiatives, we expect to see the results of their marketing efforts as they continue to establish our SDC technology in the market place. We are seeing a marked increase in potential partner companies, both in the
About PURE Bioscience
PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project,” "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.